OMCLHealthcare · Health Information ServicesThe 8 Wall Street analysts covering Omnicell, Inc. hold a median 12-month price target of $60 — +68.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Omnicell, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (61): The shares have been drifting down relative to others.
Size (39): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OMCL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +68.6% from it.
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2026 | Piper Sandler | Reiterates | Overweight | $55 → $45 |
| 31 July 2026 | Keybanc | Maintains | Overweight | $70 → $65 |
| 31 July 2026 | Wells Fargo | Maintains | Overweight | $55 → $50 |
| 29 Apr 2026 | Keybanc | Maintains | Overweight | — |
| 29 Apr 2026 | Keybanc | Maintains | Overweight | $60 → $70 |
| 23 Apr 2026 | Wells Fargo | Maintains | Overweight | — |
| 23 Apr 2026 | Wells Fargo | Maintains | Overweight | $52 → $55 |
| 6 Feb 2026 | Piper Sandler | Reiterates | Overweight | — |
| 2 Feb 2026 | Benchmark | Maintains | Buy | — |
| 8 Jan 2026 | Keybanc | Upgrade | Overweight | — |
| 5 Jan 2026 | Wells Fargo | Maintains | Overweight | — |
| 9 Dec 2025 | B of A Securities | Maintains | Neutral | — |
| 9 Dec 2025 | Benchmark | Maintains | Buy | — |
| 31 Oct 2025 | Benchmark | Maintains | Buy | — |
| 11 Aug 2025 | Piper Sandler | Maintains | Overweight | — |
| 21 July 2025 | Wells Fargo | Maintains | Overweight | — |
| 14 July 2025 | B of A Securities | Maintains | Neutral | — |
| 23 May 2025 | B of A Securities | Maintains | Neutral | — |
| 23 May 2025 | Wells Fargo | Maintains | Overweight | — |
| 14 May 2025 | Wells Fargo | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OMCL appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 18% of US stocks
Cheaper than 64% of US stocks
Cheaper than 66% of US stocks
Cheaper than 22% of US stocks
Higher than 45% of US stocks
Higher than 93% of US stocks
Higher than 61% of US stocks
Higher than 64% of US stocks
Higher than 55% of US stocks
Higher than 50% of US stocks
Higher than 58% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Omnicell, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Omnicell's president sold 6,753 shares in a transaction valued at roughly $250,000, reducing the insider's direct equity holdings by 4%.
Why it matters — A reduction in direct holdings by Omnicell's president offers OMCL watchers insight into insider selling activity at the company.
Omnicell raised its 2026 EPS outlook following a strong second quarter, though rising memory-chip costs and delayed hospital purchases may pressure margins.
Why it matters — Investors in Omnicell should note that while the company's earnings outlook has improved, margin pressure from higher input costs and slower customer spending could offset those gains.
Omnicell's shares fell 20.1% over the past month, reflecting booking uncertainty, margin pressure, and refresh-cycle risks. The decline comes even as the company maintains a higher 2026 profit outlook.
Why it matters — OMCL watchers would care because the sharp monthly drop signals growing investor concern over bookings and margins despite a more favorable longer-term profit outlook.
Zacks Investment Research highlights Omnicell as a strong value stock, based on its Zacks Style Scores feature that helps investors identify strong stocks across value, growth, and momentum categories.
Why it matters — A OMCL watcher would care because the piece signals that Omnicell is being positively recognized for its value characteristics in Zacks' widely used stock-screening methodology.
Omnicell's Q2 earnings call highlighted momentum for its Titan XT and OmniSphere products and raised its profit outlook, though customer approval timing continues to weigh on product bookings.
Why it matters — OMCL watchers would care because the update points to strong product momentum and improved profitability expectations, offset by headwinds in booking conversions related to customer approval cycles.
The 8 Wall Street analysts covering Omnicell, Inc. have a median 12-month price target of $60, with estimates ranging from $45 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Omnicell, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Omnicell, Inc. 98 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Omnicell, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +68.6% from the last close, and Ticker Nerd's factor model ranks Omnicell, Inc. 98 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Omnicell, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OMCL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $70 over the next 12 months.
Omnicell, Inc. returned +11.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Omnicell Inc. operates as a provider of medication management solutions and adherence tools within the healthcare industry.
The most recent item we track (The Motley Fool, 20 Aug 2026): "Omnicell President Sells 6,753 Shares". Omnicell's president sold 6,753 shares in a transaction valued at roughly $250,000, reducing the insider's direct equity holdings by 4%.
Omnicell Inc. operates as a provider of medication management solutions and adherence tools within the healthcare industry. Its primary function is to optimize medication management and supply chain processes in healthcare facilities, aiming to enhance safety and efficiency. The company offers automated dispensing systems, pharmacy automation equipment, and software solutions tailored for acute care hospitals, long-term care settings, and other healthcare facilities. Notable features of Omnicell’s offerings include their ability to reduce medication errors, improve workflow efficiency, and facilitate better inventory management. Omnicell plays a significant role in the healthcare sector, impacting hospitals' and pharmacies' ability to comply with stringent regulatory standards while maintaining high levels of patient care. By integrating advanced technologies such as robotics, analytics, and cloud-based solutions, Omnicell supports the digital transformation of medication management, addressing challenges associated with manual processes and medication non-adherence. The company’s market significance is evident as it continually adapts to the evolving needs of healthcare providers, ensuring effective medication administration and promoting patient safety on a global scale.
CEO Mr. Randall A. Lipps · 3,485 employees · United States · https://www.omnicell.com